Payment overview · 2025
General Payments
$413.66
22 reported records · 10 companies
Healthcare provider profile · identity verified
Marcus William Lee, MD
Allopathic & Osteopathic Physicians|Family Medicine · TULLAHOMA, TN · NPI 1457364077
Verified facts
What the public records show
CMS Open Payments records show Marcus William Lee, MD received $413.66 in general payments during 2025 across 22 reported records.
Novo Nordisk Inc accounted for 19.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 90 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 143 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 196 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $80.02 | 19.3% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $74.07 | 17.9% | 4 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $64.54 | 15.6% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $48.42 | 11.7% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $35.51 | 8.6% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $30.45 | 7.4% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $29.07 | 7.0% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $20.02 | 4.8% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $17.41 | 4.2% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $14.15 | 3.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $413.66 | 22 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $64.54 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $49.55 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $49.55 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $48.42 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $35.51 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $33.23 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $30.45 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $30.45 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $29.07 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $24.52 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $24.33 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $20.02 | 1 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $17.41 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $14.15 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 143 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 196 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
34 | 16 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
36 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
90 | 28 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
143 | 37 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
196 | 38 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 649 | 215 |
| Gabapentin | Gabapentin | 532 | 140 |
| Lisinopril | Lisinopril | 502 | 174 |
| Atorvastatin Calcium | Atorvastatin Calcium | 499 | 169 |
| Levothyroxine Sodium | Levothyroxine Sodium | 456 | 140 |
| Ezetimibe | Ezetimibe | 394 | 150 |
| Famotidine | Famotidine | 364 | 150 |
| Amlodipine Besylate | Amlodipine Besylate | 347 | 110 |
| Omeprazole | Omeprazole | 326 | 124 |
| Hydrochlorothiazide | Hydrochlorothiazide | 320 | 94 |
| Alprazolam | Alprazolam | 301 | 46 |
| Metformin Hcl | Metformin Hcl | 233 | 76 |
| Pantoprazole Sodium | Pantoprazole Sodium | 205 | 81 |
| Ozempic | Semaglutide | 196 | 38 |
| Metoprolol Succinate | Metoprolol Succinate | 185 | 63 |
| Tamsulosin Hcl | Tamsulosin Hcl | 184 | 65 |
| Escitalopram Oxalate | Escitalopram Oxalate | 181 | 62 |
| Duloxetine Hcl | Duloxetine Hcl | 156 | 45 |
| Trazodone Hcl | Trazodone Hcl | 156 | 45 |
| Losartan Potassium | Losartan Potassium | 144 | 49 |
| Mounjaro | Tirzepatide | 143 | 37 |
| Donepezil Hcl | Donepezil Hcl | 141 | 43 |
| Glimepiride | Glimepiride | 141 | 42 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 134 | 63 |
| Furosemide | Furosemide | 134 | 55 |
| Azelastine Hcl | Azelastine Hcl | 131 | 69 |
| Pregabalin | Pregabalin | 121 | 41 |
| Tramadol Hcl | Tramadol Hcl | 120 | 36 |
| Potassium Chloride | Potassium Chloride | 118 | 40 |
| Telmisartan | Telmisartan | 117 | 38 |
| Quetiapine Fumarate | Quetiapine Fumarate | 116 | 25 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 115 | 21 |
| Metoprolol Tartrate | Metoprolol Tartrate | 115 | 34 |
| Fluticasone Propionate | Fluticasone Propionate | 114 | 59 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 113 | 26 |
| Carvedilol | Carvedilol | 112 | 38 |
| Metformin Hcl Er | Metformin Hcl | 110 | 39 |
| Simvastatin | Simvastatin | 108 | 33 |
| Amitriptyline Hcl | Amitriptyline Hcl | 100 | 30 |
| Ropinirole Hcl | Ropinirole Hcl | 100 | 33 |
| Finasteride | Finasteride | 93 | 31 |
| Montelukast Sodium | Montelukast Sodium | 92 | 36 |
| Sertraline Hcl | Sertraline Hcl | 91 | 26 |
| Jardiance | Empagliflozin | 90 | 28 |
| Pravastatin Sodium | Pravastatin Sodium | 90 | 32 |
| Warfarin Sodium | Warfarin Sodium | 90 | 16 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 87 | 26 |
| Atenolol | Atenolol | 86 | 25 |
| Clonazepam | Clonazepam | 78 | 13 |
| Zolpidem Tartrate | Zolpidem Tartrate | 78 | 22 |
| Memantine Hcl | Memantine Hcl | 75 | 19 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 72 | 18 |
| Eliquis | Apixaban | 71 | 17 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 69 | 21 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 69 | 21 |
| Clopidogrel | Clopidogrel Bisulfate | 68 | 29 |
| Allopurinol | Allopurinol | 67 | 25 |
| Bupropion Xl | Bupropion Hcl | 67 | 23 |
| Spironolactone | Spironolactone | 66 | 25 |
| Promethazine Hcl | Promethazine Hcl | 65 | 20 |
| Meloxicam | Meloxicam | 64 | 29 |
| Tizanidine Hcl | Tizanidine Hcl | 64 | 21 |
| Doxepin Hcl | Doxepin Hcl | 63 | 20 |
| Testosterone Cypionate | Testosterone Cypionate | 63 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 62 | 29 |
| Prednisone | Prednisone | 60 | 34 |
| Ondansetron Hcl | Ondansetron Hcl | 59 | 29 |
| Mirtazapine | Mirtazapine | 58 | 24 |
| Baclofen | Baclofen | 57 | 19 |
| Buspirone Hcl | Buspirone Hcl | 57 | 22 |
| Aripiprazole | Aripiprazole | 56 | 17 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 56 | suppressed |
| Diazepam | Diazepam | 56 | 11 |
| Lorazepam | Lorazepam | 55 | suppressed |
| Nifedipine Er | Nifedipine | 54 | 18 |
| Citalopram Hbr | Citalopram Hydrobromide | 53 | 14 |
| Liothyronine Sodium | Liothyronine Sodium | 53 | 18 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 52 | 49 |
| Fluoxetine Hcl | Fluoxetine Hcl | 51 | 17 |
| Topiramate | Topiramate | 51 | 13 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 48 | 41 |
| Lamotrigine | Lamotrigine | 48 | suppressed |
| Fluconazole | Fluconazole | 47 | 30 |
| Nebivolol Hcl | Nebivolol Hcl | 47 | 14 |
| Celecoxib | Celecoxib | 46 | 16 |
| Clonidine Hcl | Clonidine Hcl | 46 | 28 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 46 | 13 |
| Januvia | Sitagliptin Phosphate | 45 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 44 | 16 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 43 | 16 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 43 | 38 |
| Sucralfate | Sucralfate | 41 | 11 |
| Nystatin | Nystatin | 39 | 17 |
| Azithromycin | Azithromycin | 38 | 35 |
| Farxiga | Dapagliflozin Propanediol | 36 | 12 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 36 | 15 |
| Valacyclovir | Valacyclovir Hcl | 36 | 17 |
| Chlorthalidone | Chlorthalidone | 35 | 20 |
| Linzess | Linaclotide | 34 | 16 |
| Paroxetine Hcl | Paroxetine Hcl | 34 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 34 | suppressed |
| Trulicity | Dulaglutide | 33 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 33 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 32 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 32 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 32 | 21 |
| Novolog Flexpen | Insulin Aspart | 32 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 32 | 12 |
| Xarelto | Rivaroxaban | 31 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 30 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 30 | 22 |
| Xanax | Alprazolam | 30 | suppressed |
| Glipizide | Glipizide | 29 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 29 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 29 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 28 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 28 | 18 |
| Ibuprofen | Ibuprofen | 28 | 14 |
| Myrbetriq | Mirabegron | 28 | 11 |
| Cefdinir | Cefdinir | 27 | 26 |
| Eszopiclone | Eszopiclone | 26 | 11 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 26 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 26 | suppressed |
| Primidone | Primidone | 25 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 25 | suppressed |
| Rybelsus | Semaglutide | 25 | suppressed |
| Valsartan | Valsartan | 25 | suppressed |
| Vascepa | Icosapent Ethyl | 25 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 24 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 24 | 17 |
| Terazosin Hcl | Terazosin Hcl | 24 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 23 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 23 | suppressed |
| Ramipril | Ramipril | 23 | 11 |
| Synthroid | Levothyroxine Sodium | 23 | suppressed |
| Temazepam | Temazepam | 23 | suppressed |
| Bumetanide | Bumetanide | 22 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 22 | suppressed |
| Olanzapine | Olanzapine | 21 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 21 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 21 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 20 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Estradiol | Estradiol | 19 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 19 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 19 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 18 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 18 | suppressed |
| Tradjenta | Linagliptin | 18 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 17 | suppressed |
| Levetiracetam | Levetiracetam | 17 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 17 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 17 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Lovastatin | Lovastatin | 16 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 16 | 15 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 16 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 16 | suppressed |
| Ondansetron Odt | Ondansetron | 15 | suppressed |
| Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 15 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 15 | suppressed |
| Clonidine | Clonidine | 14 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 14 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | suppressed |
| Torsemide | Torsemide | 14 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 13 | 12 |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Levemir | Insulin Detemir | 13 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 13 | suppressed |
| Verapamil Sr | Verapamil Hcl | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 12 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 12 | suppressed |
| Cephalexin | Cephalexin | 12 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Methylphenidate Er | Methylphenidate Hcl | 12 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Carbamazepine | Carbamazepine | 11 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Misoprostol | Misoprostol | 11 | suppressed |
| Rivastigmine | Rivastigmine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $413.66 · 22 records | Novo Nordisk Inc | AIRSUPRA, CAPLYTA, Cologuard Collection Kit, Kerendia, Leqembi, MOUNJARO, OTEZLA, Ozempic, QULIPTA, REPATHA, UBRELVY, VERQUVO, VRAYLAR, Wegovy | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error